As host of the BIO Buzz Center during the 2018 BIO CEO & Investor Conference, Life Science Leader magazine had the opportunity to conduct video interviews with a number of industry executives and thought leaders. One of these executives, Jeremy Levin, D.Phil, MB BChir, is the CEO of Ovid Therapeutics. But Levin also has a leadership responsibility at BIO as the chair of an opioid crisis working group. This past November, BIO released a set of priorities for unleashing the power of innovation to develop solutions to prescription opioid abuse and addiction, which presently in the United States has reached epidemic proportions. Below is my short BIO Buzz Center video interview with Levin, who discusses some of the challenges the group faces in developing needed solutions.